Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure.
Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure.
复制标题
DOI：
10.1007/s10147-006-0600-7
复制
发表时间：
2006-10-01
影响因子：
3.3
通讯作者：
Ogawa, Osamu
中科院分区：
文献类型：
--
作者：
Mitsumori, Michihide;Sasaki, Yoshihide;Ogawa, Osamu
背景技术背景：我们在此报告了根治性放疗联合新辅助激素治疗（NHT）治疗III期（国际抗癌联盟[UICC] 1997：UICC 97）前列腺癌的临床结果。前列腺特异性抗原（PSA）失败的生存率进行了评估，根据两种不同的定义，每个定义的适当性进行了讨论。方法：1997年10月至2000年12月，27例III期前列腺癌患者参加了这项研究。中位治疗前PSA水平为29 ng/ml（范围：7.4-430 ng/ml）。Gleason评分（GS）≥ 7分者22例（81%）。所有患者均接受3个月的NHT与促黄体生成素释放激素（LH-RH）类似物，并在前2周内联合抗雄激素（氟替卡松），随后接受70-戈伊外束放射治疗（EBRT），分35次。最初的46戈伊是用四野技术，而其余的是用动态适形技术。结果：中位随访时间为63个月。PSA水平降至正常范围（
BACKGROUND: We herein report the clinical outcome of radical radiation therapy combined with neoadjuvant hormonal therapy (NHT) for stage III (International Union Against Cancer [UICC] 1997: UICC 97) prostate cancer. Prostate-specific antigen (PSA) failure-free survival was assessed according to two different definitions, and the appropriateness of each definition is discussed.METHODS: Between October 1997 and December 2000, 27 patients with stage III prostate cancer were enrolled in this study. The median pretreatment PSA level was 29 ng/ml (range, 7.4-430 ng/ml). The Gleason score (GS) was 7 or more in 22 patients (81%). All patients received 3 months of NHT with a luteinizing hormone-releasing hormone (LH-RH) analogue, in combination with an antiandrogen (flutamide), given during the first 2 weeks, followed by 70-Gy external-beam radiation therapy (EBRT) in 35 fractions. The initial 46 Gy was given with a four-field technique, while the remainder was given with a dynamic conformal technique. No adjuvant hormonal therapy (AHT) was given.RESULTS: The median follow-up time was 63 months. PSA levels decreased to the normal range (